CALLICUTT JACK W 4

4 · GALECTIN THERAPEUTICS INC · Filed Nov 19, 2025

Insider Transaction Report

Form 4

Period: 2025-11-17

GALECTIN THERAPEUTICS INCGALT

CALLICUTT JACK W

Chief Financial Officer

Transactions

Exercise/Conversion
Common stock
2025-11-17$1.98/sh+9,586$18,980→ 17,200 total
Exercise/Conversion
Common stock
2025-11-18$1.98/sh+28,100$55,638→ 35,714 total
Sale
Common stock
2025-11-18$6.22/sh−28,100$174,866→ 7,614 total
Exercise/Conversion
Stock option (right to buy)
2025-11-17−9,586→ 28,120 total
Exercise: $1.98From: 2022-06-30Exp: 2032-01-24→ Common stock (9,586 underlying)
Exercise/Conversion
Stock option (right to buy)
2025-11-18−28,120→ 0 total
Exercise: $1.98From: 2022-06-30Exp: 2032-12-04→ Common stock (28,120 underlying)
Sale
Common stock
2025-11-17$6.03/sh−9,586$57,820→ 7,614 total
Exercise/Conversion
Common stock (right to buy)
2025-11-18−18,190→ 0 total
Exercise: $1.11From: 2023-06-30Exp: 2034-01-26→ Common stock (18,190 underlying)
Exercise/Conversion
Common stock
2025-11-17$1.23/sh+2,323$2,857→ 9,937 total
Sale
Common stock
2025-11-17$6.03/sh−2,323$14,012→ 7,614 total
Exercise/Conversion
Common stock
2025-11-17$1.11/sh+19,701$21,868→ 27,315 total
Exercise/Conversion
Common stock
2025-11-18$1.11/sh+18,210$20,213→ 25,824 total
Sale
Common stock
2025-11-17$6.03/sh−19,701$118,831→ 7,614 total
Sale
Common stock
2025-11-18$6.22/sh−18,210$113,321→ 7,614 total
Exercise/Conversion
Stock option (right to buy)
2025-11-17−19,701→ 18,190 total
Exercise: $1.11From: 2023-06-30Exp: 2034-01-26→ Common stock (19,701 underlying)
Exercise/Conversion
Stock option (right to buy)
2025-11-17−2,323→ 48,750 total
Exercise: $1.23From: 2025-06-30Exp: 2035-01-22→ Common stock (2,323 underlying)

Footnotes (6)

[F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
[F2]The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023.
[F3]The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024.
[F4]The options vests as follows: 25% on June 30, 2025, with 25% scheduled to vest on each of December 31, 2025, June 30, 2026, on December 31, 2026.
[F5]The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
[F6]The shares were sold in multiple transactions at prices ranging from $6.00 to $6.30. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Documents

1 file

4
form4.xmlPrimary
FORM 4